- Home
- XTNT vs CGTX Comparison
XTNT vs CGTX Comparison
Compare XTNT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XTNT | CGTX |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.7M | 94.5M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XTNT | CGTX |
|---|---|---|
| Price | $0.60 | $1.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.50 | ★ $3.33 |
| AVG Volume (30 Days) | 90.8K | ★ 609.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $53,337,000.00 | N/A |
| Revenue This Year | $15.08 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $0.22 |
| 52 Week High | $0.95 | $3.83 |
Technical Indicators
Market Signals| Indicator | XTNT | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 51.98 |
| Support Level | $0.55 | $1.00 |
| Resistance Level | $0.68 | $1.19 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 33.94 | 75.00 |
Price Performance
Historical ComparisonAbout XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.